Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson’s disease alpha-synuclein transgenic mice

Experimental and Molecular Medicine

Volumn 48, Issue 7, 2016, Pages

  Ye, Minsook ^a   Chung, Hwan Suck ^b   Lee, Chanju ^a   Song, Joo Hyun ^a   Shim, Insop ^a   Kim, Youn Sub ^c   Bae, Hyunsu ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BEE VENOM; PHOSPHOLIPASE A2; SNCA PROTEIN, HUMAN;

ANIMAL; BEE; DISEASE MODEL; DRUG EFFECTS; ENZYME THERAPY; ENZYMOLOGY; GENETICS; HUMAN; MICROGLIA; MOTOR ACTIVITY; MOUSE; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; POINT MUTATION; SPINAL CORD; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BEE VENOMS; BEES; DISEASE MODELS, ANIMAL; ENZYME THERAPY; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; MOTOR ACTIVITY; PARKINSON DISEASE; PHOSPHOLIPASES A2; POINT MUTATION; SPINAL CORD;

EID: 85021752918     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2016.49     Document Type: Article

References (44)

1. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002; 34: 521–533.
2. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. AnnNYAcad Sci 2003; 991: 214–228.
3. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004; 46: 402–409.
4. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine administration. Ann Neurol 2003; 54: 599–604.
5. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002; 68: 325–340.
6. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006; 70: 373–381.
7. Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 2012; 60: 251–266.
8. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006; 24: 157–165.
9. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013; 5: 113–139.
10. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404–412.
11. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010; 58: 588–598.
12. Kwon YB, Lee HJ, Han HJ, Mar WC, Kang SK, Yoon OB et al. The water-soluble fraction of bee venom produces antinociceptive and antiinflammatory effects on rheumatoid arthritis in rats. Life Sci 2002; 71: 191–204.
13. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther 2007; 115: 246–270.
14. Cho SY, Shim SR, Rhee HY, Park HJ, Jung WS, Moon SK et al. Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 948–952.
15. Mirshafiey A. Venom therapy in multiple sclerosis. Neuropharmacology 2007; 53: 353–361.
16. Chung ES, Kim H, Lee G, Park S, Bae H. Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells. Brain Behav Immun 2012; 26: 1322–1330.
17. Habermann E. Bee and wasp venoms. Science 1972; 177: 314–322.
18. Linderoth L, Peters GH, Jorgensen K, Madsen R, Andresen TL. Synthesis of sn-1 functionalized phospholipids as substrates for secretory phospholipase A2. Chem Phys Lipids 2007; 146: 54–66.
19. Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J 1991; 5: 2068–2077.
20. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. JBiolChem1994; 269: 13057–13060.
21. Mukherjee AB, Miele L, Pattabiraman N. Phospholipase A2 enzymes: regulation and physiological role. Biochem Pharmacol 1994; 48: 1–10.
22. Granata F, Frattini A, Loffredo S, Del Prete A, Sozzani S, Marone G et al. Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages. Eur J Immunol 2006; 36: 1938–1950.
23. Dennis EA. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997; 22: 1–2.
24. Fenard D, Lambeau G, Maurin T, Lefebvre JC, Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Pharmacol 2001; 60: 341–347.
25. Nakashima S, Kitamoto K, Arioka M. The catalytic activity, but not receptor binding, of sPLA2s plays a critical role for neurite outgrowth induction in PC12 cells. Brain Res 2004; 1015: 207–211.
26. Ogawa N. Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era. Eur Neurol 1997; 38(Suppl 1): 2–5.
27. Lu J, Sun F, Ma H, Qing H, Deng Y. Comparison between alpha-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model. Biochem Biophys Res Commun 2015; 464: 988–993.
28. Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Yamada S, Matsubara E et al. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res 2009; 1250: 232–241.
29. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization. Mol Neurodegener 2013; 8: 5.
30. Chalimoniuk M, Stolecka A, Zieminska E, Stepien A, Langfort J, Strosznajder JB. Involvement of multiple protein kinases in cPLA2 phosphorylation, arachidonic acid release, and cell death in in vivo and in vitro models of 1-methyl-4-phenylpyridinium-induced parkinsonism–the possible key role of PKG. J Neurochem 2009; 110: 307–317.
31. Stefanis L. alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: a009399.
32. Oliveras-Salva M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener 2013; 8: 44.
33. Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J et al. Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener 2013; 8: 17.
34. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA 2015; 112: E5308–E5317.
35. Kraft AD, Harry GJ. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 2011; 8: 2980–3018.
36. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77–98.
37. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285–1291.
38. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. JNeurosci2009; 29: 13435–13444.
39. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 2011; 12: 388–399.
40. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014; 11: 98.
41. Olah M, Biber K, Vinet J, Boddeke HW. Microglia phenotype diversity. CNS Neurol Disord Drug Targets 2011; 10: 108–118.
42. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. JNeurosci2008; 28: 11650–11661.
43. Kim H, Lee H, Lee G, Jang H, Kim SS, Yoon H et al. Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor. Kidney Int 2015; 88: 550–559.
44. Chung ES, Lee G, Lee C, Ye M, Chung HS, Kim H et al. Bee venom phospholipase A2, a novel Foxp3+ regulatory T cell inducer, protects dopaminergic neurons by modulating neuroinflammatory responses in a mouse model of Parkinson's Disease. J Immunol 2015; 195: 4853–4860.